Chemistry:Lokivetmab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | interleukin 31 (IL-31) |
| Clinical data | |
| Trade names | Cytopoint |
| Routes of administration | subcutaneous injection |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] It acts against interleukin 31 (IL-31),[2] which is a cytokine involved in causing itchiness (pruritus).[2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.[3]
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016,[3] and it was approved by the European Medicines Agency in 2017.[4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.[4]
References
- ↑ "Zoetis earns license for Cytopoint skin therapy". Veterinary Practice News. 4 January 2017. https://www.veterinarypracticenews.com/zoetis-earns-license-for-cytopoint-skin-therapy/.
- ↑ 2.0 2.1 "Atopic Dermatitis in Animals and People: An Update and Comparative Review". Veterinary Sciences 4 (3): 37. July 2017. doi:10.3390/vetsci4030037. PMID 29056696.
- ↑ 3.0 3.1 McKay, Lindsay (13 July 2017). "Making a difference for dogs with atopic dermatitis: When to use Apoquel and when to use Cytopoint". https://www.dvm360.com/view/making-difference-dogs-with-atopic-dermatitis-when-use-apoquel-and-when-use-cytopoint.
- ↑ 4.0 4.1 "First antibody therapy in veterinary medicine launched for dogs in the UK". The Veterinary Record 181 (1): 6–7. July 2017. doi:10.1136/vr.j3147. PMID 28667135.
External links
- "Lokivetmab". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/lokivetmab.
 |  |
